SCANGOS GEORGE A
Known title: President and CEOCIK: 0001202102
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Transaction History
| A | ▲ Buy | Grant | 1,057 | $118K | 3/19/2026 | View on chart |
| A | ▲ Buy | Grant | 2,158 | $241K | 3/19/2026 | View on chart |
| A | ▲ Buy | Grant | 1,819 | $220K | 3/14/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 10,056 | $95K | 2/24/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 10,964 | $108K | 2/18/2025 | View on chart |
| VIR | ▼ Sell | Other | 598,270 | $0 | 10/23/2024 | View on chart |
| VIR | ▼ Sell | Other | 598,270 | $0 | 10/23/2024 | View on chart |
| VIR | ▼ Sell | Other | 598,270 | $0 | 10/23/2024 | View on chart |
| VIR | ▼ Sell | Other | 598,270 | $0 | 10/23/2024 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2024 | View on chart |
| A | ▼ Sell | Gift | 3,443 | $501K | 5/29/2024 | View on chart |
| A | ▼ Sell | Gift | 3,443 | $501K | 5/29/2024 | View on chart |
| A | ▲ Buy | Grant | 1,678 | $247K | 3/15/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 17,722 | $207K | 2/26/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 10,028 | $101K | 2/22/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 16,872 | $172K | 2/20/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 10,878 | $111K | 2/16/2024 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 10/17/2023 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 10/17/2023 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 10/17/2023 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 10/17/2023 | View on chart |
| VIR | ▼ Sell | Other | 3,500,000 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 111,644 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 827,151 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 111,644 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 1,750,000 | $0 | 9/15/2023 | View on chart |
| VIR | ▼ Sell | Other | 827,151 | $0 | 9/15/2023 | View on chart |
| A | ▲ Buy | Grant | 1,658 | $227K | 3/16/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 4,239 | $96K | 2/24/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 10,880 | $256K | 2/24/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 12,631 | $328K | 2/23/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 6,474 | $186K | 2/21/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 11,382 | $319K | 2/21/2023 | View on chart |
| VIR | ▼ Sell | Open Market | 9,894 | $250K | 2/17/2023 | View on chart |
| VIR | ▼ Sell | Other | 64,930 | $0 | 1/18/2023 | View on chart |
| VIR | ▼ Sell | Other | 64,930 | $0 | 1/18/2023 | View on chart |
| VIR | ▼ Sell | Other | 49,984 | $0 | 12/21/2022 | View on chart |
| VIR | ▼ Sell | Other | 49,984 | $0 | 12/21/2022 | View on chart |
| VIR | ▼ Sell | Other | 49,984 | $0 | 12/21/2022 | View on chart |
| VIR | ▼ Sell | Other | 49,984 | $0 | 12/21/2022 | View on chart |
| A | ▲ Buy | Grant | 1,785 | $244K | 3/17/2022 | View on chart |
| VIR | ▲ Buy | Grant | 111,000 | $0 | 3/10/2022 | View on chart |
| VIR | ▼ Sell | Open Market | 17,726 | $543K | 2/18/2022 | View on chart |
| VIR | ▼ Sell | Open Market | 10,024 | $320K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M
Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.